CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 16,177	$ 9,746
Prepaid expenses and other current assets	734	92
Total current assets	16,911	9,838
Property and equipment, net	356	431
Operating lease right-of-use asset	323	475
Other assets	29	34
Total assets	17,619	10,778
Current liabilities:
Accounts payable	4,013	7,805
Accrued clinical trials expenses	5,641	2,051
Accrued compensation	1,020	1,112
Excise tax payable	569
Other accrued expenses	2,934	740
Current portion of convertible notes at fair value, including related party amount of $0 and $38,834 at September 30, 2023 and December 31, 2022, respectively		70,866
Total current liabilities	14,177	82,574
Convertible notes at fair value, including related party amount of $0 and $23,132, at September 30, 2023 and December 31, 2022, respectively		60,426
Operating lease liability	52	242
Warrant liability	2,172
Contingent consideration liability	81,161
Embedded forward purchase agreements and derivative liabilities	48,453
Total liabilities	146,015	143,242
Commitments and contingencies
Convertible preferred stock issuable in series, $0.0001 par value; 44,666,035 shares authorized as of December 31, 2022; 21,257,708 shares issued and outstanding at December 31, 2022; liquidation preference of $141,920 at December 31, 2022		137,949
AEON Biopharma, Inc. stockholders' deficit:
Class A common stock, $0.0001 par value; 500,000,000 and 207,450,050 shares authorized, 37,159,600 and 138,848,177 shares issued and 37,159,600 and 138,825,356 shares outstanding at September 30, 2023 and December 31, 2022, respectively	4	14
Additional paid-in capital	379,669	187,348
Subscription receivables	(60,710)
Accumulated deficit	(447,359)	(474,839)
Treasury stock, at cost, 0 and 22,821 shares at September 30, 2023 and December 31, 2022, respectively		(23)
Total AEON Biopharma, Inc. stockholders' deficit	(128,396)	(287,500)
Non-controlling interest		17,087
Total stockholders' deficit	(128,396)	(270,413)
Total liabilities, convertible preferred stock and stockholders' deficit	$ 17,619	$ 10,778